Obesity study: NNC0487-0111
Official title A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
ClinicalTrials.gov ID: NCT07567001
What this study is testing
What is NNC0487-0111?
An investigational once‑weekly injectable medicine being studied as a potential treatment for obesity in people with heart failure with preserved or mildly reduced ejection fraction.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if NNC0487-0111 is safe and works for treating heart failure with preserved or mildly reduced ejection fraction in people who are overweight.
- Who it's for
- Adults who have heart failure with preserved or mildly reduced ejection fraction and are overweight.
- What's involved
- Participants will be randomly assigned to receive either NNC0487-0111 or a placebo by injection once a week, along with study visits and tests.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Body Mass Index (BMI) greater than or equal to (\>=) 30 kilograms per square metre (kg/m\^2) at screening.
- Diagnosis of HF with New York Heart Association (NYHA) class II-IV and in stable condition at screening, at the discretion of the investigator.
You likely can't join if
- MI, stroke, unstable angina pectoris or worsening HF leading to either hospitalization or intravenous loop diuretics within 30 days prior to the day...
- HF due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, Chagas...
- requiring home oxygen; or - ongoing oral corticosteroid therapy; or - hospital for COPD Exacerbation within 12 months prior to screening.
- History of type 1 diabetes.
- Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial...
- Glycated haemoglobin (HbA1c) greater than (\>) 10 percent (%) (86 [millimoles per mole] mmol/mol) as measured by local or central laboratory at...
The study team makes the final eligibility decision.
Where it is enrolling
- Alexander City, Alabama, United States
- Fairhope, Alabama, United States
- Gilbert, Arizona, United States
- Glendale, Arizona, United States
- Alhambra, California, United States
- Beverly Hills, California, United States
- Chula Vista, California, United States
- Concord, California, United States
- Covina, California, United States
- Fremont, California, United States
- Granada Hills, California, United States
- Huntington Beach, California, United States
- Huntington Park, California, United States
- Long Beach, California, United States
- Los Alamitos, California, United States
- Northridge, California, United States
- Palm Springs, California, United States
- San Diego, California, United States
- Santa Maria, California, United States
- Santa Rosa, California, United States
+ 417 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Alexander City, Alabama, United States; Fairhope, Alabama, United States; Gilbert, Arizona, United States; Glendale, Arizona, United States; Alhambra, California, United States; Beverly Hills, California, United States and 431 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.